Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...
Principais autores: | Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
BMJ Publishing Group
2022
|
Registros relacionados
-
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Josef S Smolen, et al.
Publicado em: (2022-11-01) -
Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
por: Coates, L, et al.
Publicado em: (2018) -
Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
por: Coates, LC, et al.
Publicado em: (2021) -
Ixekizumab in the treatment of psoriatic arthritis
por: Yu. L. Korsakova, et al.
Publicado em: (2024-12-01) -
Methotrexate in psoriasis and psoriatic arthritis
por: Coates, L, et al.
Publicado em: (2020)